Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.6%

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) fell 5.6% on Friday . The company traded as low as $37.73 and last traded at $37.77. 187,101 shares traded hands during trading, a decline of 81% from the average session volume of 1,007,398 shares. The stock had previously closed at $40.02.

Analyst Ratings Changes

A number of brokerages recently weighed in on TWST. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, July 9th. TD Cowen raised their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, June 13th. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a "buy" rating and a $53.00 price target for the company. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.22.

Twist Bioscience Price Performance

The stock has a 50 day moving average price of $48.47 and a 200-day moving average price of $42.64.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business's revenue was up 27.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.01) earnings per share. Research analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the business's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now owns 88,837 shares of the company's stock, valued at $3,547,261.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Twist Bioscience news, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the sale, the insider now owns 78,996 shares in the company, valued at $3,154,310.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paula Green sold 1,137 shares of the business's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the sale, the senior vice president now owns 88,837 shares in the company, valued at approximately $3,547,261.41. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,483 shares of company stock valued at $781,448. Insiders own 3.92% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the company. Artisan Partners Limited Partnership boosted its position in shares of Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company's stock worth $137,241,000 after acquiring an additional 1,961,621 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its position in shares of Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company's stock worth $131,835,000 after acquiring an additional 99,511 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company's stock worth $46,732,000 after acquiring an additional 284,884 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock worth $42,116,000 after acquiring an additional 132,770 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock worth $33,168,000 after acquiring an additional 613,057 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.